Acamprosate calcium

• CAT Number: I004844
• CAS Number: 77337-73-6
• Molecular Formula: C10H20CaN2O8S2
• Molecular Weight: 400.47
• Purity: ≥95%
• Synonyms: calcium;3-acetamidopropane-1-sulfonate
• Target: GABA Receptor
• Solubility: 10 mM in H2O
• Storage: 2-8°C
• InChI: InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2
• InChIKey: BUVGWDNTAWHSKI-UHFFFAOYSA-L
• SMILES: CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]

Acamprosate (Cat No.: I004844) is a synthetic compound with a chemical structure resembling both the neurotransmitter GABA and the neuromodulator taurine. It functions as a GABA receptor agonist and a modulator of the glutamate system. Acamprosate’s unique pharmacological profile makes it valuable in the treatment of alcohol dependence, as it helps stabilize the brain’s neurotransmitter balance during the withdrawal phase. If you need to, please contact us in time, and we will reply to you as soon as possible within 24 hours.

Reference

[1]. Gahr M, et al. Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy.Nervenarzt. 2012 Aug 15.
[2]. Pa?ucha-Poniewiera A, Pilc A. Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6.
[3]. Hinton DJ, et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology. 2012 Jun;62(8):2480-8.
[4]. Preuss UW. Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.). Alcohol Clin Exp Res. 2012 Jun;36(6):967-9. doi: 10.1111/j.1530-0277.2012.01827.x.
[5]. Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag. 2012;8:45-53.